Bcxp.Wa
BCXP.WA operates in the pharmaceuticals industry, focusing on drug development and research, primarily generating revenue through product sales and partnerships in the healthcare sector.
Business. BCXP.WA operates in the pharmaceuticals industry, focusing on drug development and research, primarily generating revenue through product sales and partnerships in the healthcare sector.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BCXP.WA operates in the pharmaceuticals industry, focusing on drug development and research, primarily generating revenue through product sales and partnerships in the healthcare sector.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative approach to leverage. However, the company's liquidity is rated as medium, and its current ratio of 12.34 suggests a strong short-term liquidity position. Despite this, the company's operating cash flow is negative at -17.57 million PLN, and its free cash flow is also negative at -14.57 million PLN, indicating a lack of cash generation from operations.
Profitability metrics show a return on equity of -38.78% and a return on assets of -35.59%, both significantly below the industry median for pharmaceutical companies. The company's operating income is negative at -15.03 million PLN, and its net income is also negative at -14.90 million PLN, indicating a lack of profitability. These figures suggest that the company is not generating sufficient returns to meet industry standards.
The company's revenue is reported as 0.0 PLN, and there is no detailed breakdown of segments or geographic exposure provided in the available data. This lack of information makes it difficult to assess the company's revenue concentration or geographic diversification. However, the absence of revenue data raises concerns about the company's ability to generate income from its operations.
The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The company's operating income and net income have both declined, and there is no indication of a turnaround in the near term. The absence of revenue data further complicates the assessment of the company's growth potential.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges in the future. The company's capital structure is conservative, with a low debt-to-equity ratio, but the negative cash flow from operations could impact its ability to maintain this structure.
Recent events and filings do not provide specific details about the company's operations or financial performance. The lack of detailed information in the available data makes it difficult to assess the company's recent developments or strategic initiatives. The company's financial snapshot does not include any recent events or transcripts that could provide insight into its current status.
- The company has a conservative capital structure with a low debt-to-equity ratio of 0.02.
- The company's profitability metrics, including return on equity and return on assets, are significantly below industry medians.
- The company's revenue is reported as 0.0 PLN, and there is no detailed breakdown of segments or geographic exposure.
- The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance.
- The company's liquidity risk is rated as medium, and its dilution risk is rated as low.
- **margin_outlook_rationale**: The company's negative operating and net income suggest a deteriorating margin outlook driven by poor cost control and revenue generation.
- **rd_outlook_rationale**: No specific R&D outlook is provided in the available data, but the company's negative cash flow from operations may limit its ability to invest in R&D.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,50 |
| Revenue | —no estimate | —no estimate | 0 PLN |
| Operating income | —no estimate | —no estimate | -15,8M PLN |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- BCXP.WA Market data — financials · 2026-05-27
- Bioceltix SA Market data — analyst estimates · 2026-05-27